<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Eva</forename><surname>Krepsova</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Irena</forename><surname>Tycova</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alena</forename><surname>Sekerkova</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Clinical and Transplant Immunology</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Wohlfahrt</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Preventive Cardiology</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<address>
									<addrLine>Cardiology Centre</addrLine>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><surname>Hruba</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ilja</forename><surname>Striz</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Clinical and Transplant Immunology</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Birgit</forename><surname>Sawitzki</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Medical Immunology and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)</orgName>
								<orgName type="institution">Charit√© University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ondrej</forename><surname>Viklicky</surname></persName>
							<email>ondrej.viklicky@ikem.cz</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Nephrology</orgName>
								<orgName type="department" key="dep2">Transplant Centre</orgName>
								<orgName type="department" key="dep3">Institute for Clinical and Experimental Medicine</orgName>
								<address>
									<postCode>1958, 14021</postCode>
									<settlement>Videnska, Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Centre for Experimental Medicine</orgName>
								<orgName type="department" key="dep2">Institute for Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Transplant Laboratory</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Nephrology</orgName>
								<orgName type="department" key="dep2">Transplant Centre</orgName>
								<orgName type="department" key="dep3">Institute for Clinical and Experimental Medicine</orgName>
								<address>
									<postCode>1958, 14021</postCode>
									<settlement>Videnska, Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Biomedical Centre</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine in Plzen</orgName>
								<orgName type="institution">Charles University</orgName>
								<address>
									<settlement>Prague, Plzen</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">BE022811A633634E8B257B89F33B1A42</idno>
					<idno type="DOI">10.1186/s12882-015-0141-2</idno>
					<note type="submission">Received: 17 June 2015 Accepted: 6 August 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:36+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Basiliximab</term>
					<term>FOXP3</term>
					<term>Kidney transplantation</term>
					<term>rATG</term>
					<term>Rejection</term>
					<term>Tolerance</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Induction therapy can improve kidney transplantation (KTx) outcomes, but little is known about the mechanisms underlying its effects.</s><s>Methods: The mRNA levels of T cell-related genes associated with tolerance or rejection (CD247, GZMB, PRF1, FOXP3, MAN1A1, TCAIM, and TLR5) and lymphocyte subpopulations were monitored prospectively in the peripheral blood of 60 kidney transplant recipients before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx.</s><s>Patients were treated with calcineurin inhibitor-based triple immunosuppression and induction with rabbit antithymocyte globulin (rATG, n = 24), basiliximab (n = 17), or without induction (no-induction, n = 19).</s><s>A generalized linear mixed model with gamma distribution for repeated measures, adjusted for rejection, recipient/donor age and delayed graft function, was used for statistical analysis.</s></p><p><s>Results: rATG treatment caused an intense reduction in all T cell type population and natural killer (NK) cells within 7 days, then a slow increase and repopulation was observed.</s><s>This was also noticed in the expression levels of CD247, FOXP3, GZMB, and PRF1.</s><s>The basiliximab group exhibited higher CD247, GZMB, FOXP3 and TCAIM mRNA levels and regulatory T cell (Treg) counts than the no-induction group.</s><s>The levels of MAN1A1 and TLR5 mRNA expressions were increased, whereas TCAIM decreased in the rATG group as compared with those in the noinduction group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>The rATG induction therapy was associated with decreased T and NK cell-related transcript levels and with upregulation of two rejection-associated transcripts (MAN1A1 and TLR5) shortly after KTx.</s><s>Basiliximab treatment was associated with increased absolute number of Treg cells, and increased level of FOXP3 and TCAIM expression.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Long-term allograft survival requires lifelong immunosuppression, the use of which could be accompanied by several side effects <ref type="bibr" target="#b0">[1]</ref>.</s><s>For many patients triple drug regimens are not necessary due to weak alloreactive responses.</s><s>Therefore, a development of reliable tests that may help identify patients suitable for drug minimization or at risk for rejection is needed.</s><s>Several markers of rejection or operational tolerance (defined as good and stable graft function in immunosuppression free patients) have been identified <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>.</s></p><p><s>Granzyme B (GZMB) and perforin (PRF1) are effector molecules produced by cytotoxic T and natural killer (NK) cells.</s><s>Perforin forms a pore in the target cell membrane and thus facilitates the entry of granzyme B and other compounds into the cell which subsequently leads to apoptosis <ref type="bibr" target="#b8">[9]</ref>.</s><s>The urine and peripheral blood transcript levels of PRF1 and GZMB were shown to be increased in kidney transplant recipients with acute rejection <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>The Œ∂-chain of T cell receptor (CD247) is a part of T-cell receptor-CD3 complex on T cells and activating receptors on NK cells <ref type="bibr" target="#b9">[10]</ref>.</s><s>Transcription of CD247 was shown to be downregulated in peripheral blood lymphocytes from patients with long-term surviving kidneys <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>Toll-like receptor 5 (TLR5) is a member of TLR family which plays a fundamental role in the pathogen recognition and associated activation of innate immunity.</s><s>The expression of TLR5 was downregulated in operationally tolerant kidney graft recipients <ref type="bibr" target="#b4">[5]</ref>.</s><s>FoxP3 (forkhead box P3) is a key transcription factor in CD4 + CD25 + FoxP3 + regulatory T cells (Tregs), necessary for their differentiation and maintenance in the periphery <ref type="bibr" target="#b10">[11]</ref>.</s><s>Peripheral blood mRNA levels of FOXP3 were higher in patients with operational tolerance or stable kidney graft function compared to patients with chronic rejection <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>A reduced geneexpression ratio of FOXP3 to Œ±-1,2-mannosidase (MAN1A1) was observed for chronically rejecting patients <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>Alpha-1,2-mannosidases (MAN1A1) are transmembrane proteins that specifically cleave Œ±-1,2-linked mannose residues from oligosaccharides and are involved in the synthesis and maturation of N-glycoproteins <ref type="bibr" target="#b11">[12]</ref>.</s><s>TCAIM (T cell activation inhibitor, mitochondrial; previously named TOAG-1) was highly expressed during the induction and maintenance of tolerance, but was downregulated during acute rejection <ref type="bibr" target="#b5">[6]</ref>.</s></p><p><s>The induction therapy (with either lymphocytedepleting agents including rabbit anti-thymocyte globulin (rATG) or IL-2 receptor antagonist such as basiliximab) is recommended as part of the initial immunosuppressive regimen in kidney transplant recipients to reduce acute rejection and/or to allow the reduction of other components of the regimen <ref type="bibr" target="#b12">[13]</ref>.</s></p><p><s>We and others previously demonstrated that induction therapy with rATG was associated with the expansion of relative numbers of CD4 + CD25 + FoxP3 + Treg during T cell depletion <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref> and that basiliximab induction caused the transient appearance and disappearance of CD4 + CD25 low/-FoxP3 + and CD4 + CD25 + FoxP3 + Treg, respectively <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>Furthermore we showed that high ratios of CD4 + FoxP3 + Tregs to effector T cells in peripheral blood of kidney graft recipients treated with basiliximab induction in early post-transplant period were associated with the absence of rejection <ref type="bibr" target="#b13">[14]</ref>.</s><s>However, little is known about the effect of rATG and basiliximab on the expression of genes associated with rejection or operational tolerance in clinical kidney transplantation.</s><s>Therefore, in order to address this issue, we measured relative quantities of seven selected molecular markers associated with rejection or tolerance (CD247, GZMB, PRF1, MAN1A1, TLR5, FOXP3 and TCAIM) and numbers of lymphocyte subpopulations (CD3 + , CD4 + , CD8 + , NK, CD4 + FOXP3 + ) in the peripheral blood of kidney transplant recipients treated with rATG, basiliximab or no-induction.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and samples</head><p><s>Between September 2009 and November 2010, 75 consecutive recipients of kidney transplants from deceased donors were enrolled in a single-centre prospective study.</s><s>Written informed consent was obtained from all participants.</s><s>The study protocol was approved by the Ethics Committee of the Institute for Clinical and Experimental Medicine (No. 608-08-10).</s><s>Sixty patients met all of the following inclusion criteria for the study: 1) sufficient mRNA obtained during at least 7/9 sampling time-points, 2) unchanged maintenance immunosuppression, and 3) no steroid-resistant rejection.</s></p><p><s>Patients were treated in accordance with the centre's immunosuppression treatment protocol which consisted of triple maintenance therapy with a calcineurin inhibitor (CNI; tacrolimus or cyclosporine A), mycophenolate mofetil, and corticosteroids.</s><s>Patients were recruited for a specific induction therapy on the basis of personal immunologic risk factors.</s><s>Patients with a panel-reactive antibody (PRA) score ‚â• 50 % or with previous renal transplantation received 1-1.5 mg/kg/day rATG (Thymoglobulin¬Æ, Genzyme Corporation, Cambridge, MA, n = 24) in 2-7 doses during the first week after KTx.</s><s>Patients with PRA scores of 20-49 % or the ones who received a kidney from an extended criteria donor were treated with 20 mg of basiliximab (Simulect¬Æ, Novartis, Basel, Switzerland, n = 17) on the day of KTx and 4 days after.</s><s>Patients with PRA score &lt; 20 % received no induction therapy (n = <ref type="bibr" target="#b18">19)</ref>.</s></p><p><s>Peripheral blood samples were collected before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx.</s><s>Except for differences in the retransplantation frequency, mean PRA score, and donor age, the clinical characteristics did not differ significantly among the three groups (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histology and treatment of rejection</head><p><s>Kidney graft biopsies were performed on the basis of clinical indications (case biopsies) or 90 days after KTx, as defined by the protocol.</s><s>Acute rejection was diagnosed according to the Banff'05 classification <ref type="bibr" target="#b16">[17]</ref>.</s><s>Borderline changes and grade I or IIA T cell-mediated rejection were treated with 1.5-2 g of methylprednisolone.</s><s>Antibodymediated rejection was treated by plasma exchange and intravenous immunoglobulin alternately over the 10-day period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometry and isolation of peripheral blood mononuclear cells</head><p><s>Venous blood samples were collected into sterile EDTAcontaining tubes.</s><s>Lymphocytes from peripheral blood (100 ŒºL; ~1 √ó 10 6 cells) were labelled with a 4-color monoclonal antibody (mAb) panel: CYTO-STAT tetra-Chrome CD45-FITC (clone: B3821F4A)/CD56-RD1 (clone: N901/NKH1)/CD19-ECD (clone: J3-119)/CD3-PC5 (clone: UCHT1) + CD16-PE (clone: 3G8) and CD45-FITC (clone: B3821F4A)/CD4-RD1 (clone: SFCI 12T4D11)/CD8-ECD (clone: SFCI21Thy2D3)/CD3 (clone: UCHT1) (all Beckman Coulter, Brea, CA).</s></p><p><s>Extracellular staining of freshly prepared and isolated peripheral blood mononuclear cells was performed with anti-CD4-FITC (clone: RPA-T4) and anti-CD25-APC (clone: BC96) antibodies prior to intracellular staining with anti-FoxP3-PE (clone: PCH101).</s><s>Tregs were stained for intracellular FoxP3 with the Human Regulatory T Cell Staining Kit (eBioscience, San Diego, CA, USA).</s><s>An appropriate isotype control mAb (rat IgG2a-PE, cocktail of FITC and APC mouse IgG1) was used to establish the settings for FoxP3 + Treg analysis.</s></p><p><s>Stained samples were analysed in the FC 500 flow cytometer with CxP and Kaluza software (Beckman Coulter).</s><s>Flow cytometric analyses were performed with at least 100 gated events.</s><s>Lymphocyte subpopulations were defined as follows: T lymphocytes, CD45 + CD3 + ; cytotoxic T lymphocytes, CD45 + CD3 + CD8 + ; and NK cells, CD45 + CD3 ‚àí CD16 + CD56 +/-.</s><s>Because basiliximab may downregulate CD25 <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18]</ref> or interfere with some anti-CD25 mAbs used for flow cytometry <ref type="bibr" target="#b18">[19]</ref>, Tregs were defined as CD3 + CD4 + FoxP3 + .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gene expression analysis and RNA isolation</head><p><s>Peripheral blood was drawn directly into PAXgene tubes (Qiagen, Hilden, Germany), frozen, and stored at -20 ¬∞C until analysis.</s><s>Whole-blood RNA was extracted with the PAXgene Blood RNA Kit with DNAse I treatment (Qiagen).</s><s>The purity and concentration of the RNA were assessed in an ultraviolet-visible spectrophotometer (NanoDrop 2000, Thermo Scientific).</s><s>The RNA isolation method routinely used in our laboratory was validated and standardized on reference samples, to eliminate errors and ensure the same standards across all measurements.</s><s>The quality of RNA samples obtained by the standard</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>T and NK cells</head><p><s>In the rATG group, depletion of T cells (CD3 + ), the subpopulations (CD4 + T cells, CD8 + T cells, and CD4 + FoxP3 + Tregs), and NK cells were observed at 7 days post-KTx, followed by a slow repopulation (Fig. <ref type="figure">1a-d</ref>; data for CD4 + not shown).</s><s>The CD8 + T and NK cell counts reached or exceeded their pre-KTx values at 12 month.</s><s>The total cell counts for CD3 + T cells, CD4 + T cells, and CD4 + FoxP3 + Tregs, however, only reached 66, 34, and 68 % of the preKTx values respectively, at 12 month.</s><s>The total CD3 + and CD8 + T cells reached substantially higher counts at 12 month as compared to the pre-KTx values in the no-induction and basiliximab groups (CD3 + : 147 % and 155 %, CD8 + : 170 % and 257 %, respectively).</s><s>The absolute numbers of T cells, the subpopulations (CD4 + , CD8 + , and CD4 + FoxP3 + Tregs), and NK cells were lower in the rATG group compared to the no-induction and basiliximab groups during follow-up (all P &lt; 0.001; Fig. <ref type="figure">1a-d</ref>; data for CD4 + not shown).</s><s>CD8 + T cells were decreased and the Treg cells were increased in the basiliximab group as compared to the no-induction group (P &lt; 0.05 and P &lt; 0.01; Fig. <ref type="figure">1b, d</ref>).</s><s>In the basiliximab group, the number of Tregs increased soon after KTx, peaking on day 14 and then decreasing towards the pre-KTx level (Fig. <ref type="figure">1d</ref>).</s></p><p><s>In contrast to the absolute numbers, the frequency of CD4 + FoxP3 + Tregs among the CD4 + T cells was increased compared to the pre-KTx levels at day 7 in the rATG and basiliximab group.</s><s>In rATG group the Treg at the end of the follow-up period; in basiliximab group CD4 + FoxP3 + Treg frequencies decreased towards the pre-KTx levels after day 7 and remained lower compared to rATG group (P &lt; 0.001; data for Treg frequencies not shown).</s><s>In the no-induction group, the Treg frequencies were stable and lower than those of the rATG and basiliximab group throughout the follow-up period (P &lt; 0.001 and P &lt; 0.05, respectively; data for Treg frequencies not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rejection-associated transcripts</head><p><s>In all groups, transcripts for CD247, GZMB, and PRF1 decreased on day 7, thereafter increasing slowly towards their pre-KTx levels.</s><s>The transcript levels decreased to zero and were lowest among the groups (all P &lt; 0.001; Fig. <ref type="figure">2a-c</ref>) in rATG group.</s><s>Higher CD247 and GZMB expression levels (both P &lt; 0.01) were found in the basiliximab group compared to the no-induction group (Fig. <ref type="figure">2a, b</ref>).</s><s>MAN1A1 expression was highest (P &lt; 0.001) in the rATG group as compared to basiliximab and no-induction groups (Fig. <ref type="figure">2d</ref>).</s><s>In all groups, the MAN1A1 expression was increased on day 7 compared to the pre-KTx level.</s><s>MAN1A1 expression continued to increase in the rATG group, whereas it stabilized in the other two groups on day 14.</s><s>In the rATG group, the MAN1A1 expression peaked at day 21 and, thereafter, decreased towards its pre-KTx value.</s><s>Substantial differences in MAN1A1 expression were observed between the rATG group and other groups from days 21 to 90 (Fig. <ref type="figure">2d</ref>).</s><s>The TLR5 mRNA expression was higher in the rATG group than in the no-induction group (P &lt; 0.05; Fig. <ref type="figure">2e</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tolerance-associated transcripts</head><p><s>Similar to the findings for CD247, GZMB, and PRF1, the mRNA expression of FOXP3 was decreased in all groups on day 7 compared to the pre-KTx level with the most profound decrease and subsequent increase towards the pre-KTx level in the rATG group.</s><s>FOXP3 expression was lowest in the rATG group; it was higher in the basiliximab group than in the no-induction group (all P &lt; 0.001; Fig. <ref type="figure">3a</ref>).</s></p><p><s>The trend of the mRNA expression ratio of FOXP3 to MAN1A1 was similar to that of the FOXP3 expression; the ratio decreased on day 7 in all groups, with the most profound decrease and subsequent increase towards pre-KTx levels being seen in the rATG group.</s><s>The lowest ratio was found in the rATG group (all P &lt; 0.001; data not shown).</s><s>The TCAIM mRNA expression constantly increased in all groups, with basiliximab-and rATGtreated patients displaying the fastest and slowest increases, respectively, among the groups (P &lt; 0.01; Fig. <ref type="figure">3b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>To the best of our knowledge, this is the first prospective trial that aimed to evaluate the effects of different induction agents on molecular markers associated with rejection or operational tolerance in kidney transplant recipients.</s><s>We analysed the relative quantity of seven selected T cell-related transcripts, associated with operational tolerance or rejection, and lymphocyte subpopulations in KTx patients treated with different induction regimens.</s><s>In our study the rATG induction therapy was associated with profound decrease of T and NK cells, as well as T cell transcripts that are exclusively expressed by these cell types.</s><s>In rATG group the transient upregulation of MAN1A1 and TLR5 transcripts, previously shown to be associated with chronic rejection <ref type="bibr" target="#b4">[5]</ref>, was observed.</s><s>Basiliximab induction resulted in a transient increase in CD4 + FoxP3 + Tregs, accompanied by the highest peripheral expression levels of markers associated with operational tolerance (FOXP3 and TCAIM).</s></p><p><s>Many studies have documented the dose-dependent depletional effect of rATG on T and NK cells <ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>.</s><s>However, little is known about transcript-level changes due to rATG treatment.</s><s>Simon et al. described the effect of ATG induction therapy on expression of 10 immunologically relevant genes in the early post-transplant period and found decrease of GZMB and PRF1 expression <ref type="bibr" target="#b24">[25]</ref>.</s><s>We observed a profound drop in the relative mRNA quantities of CD247, GZMB, PRF1, and FOXP3 early after transplantation in rATG group.</s><s>These transcripts are expressed exclusively by T and NK cells and are present at different levels in rejecting or operationally tolerant patients <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>The profound drop was followed by a slow increase towards pre-KTx levels in rATG patients, corresponding to the depletion and progressive repopulation of the aforementioned cell types.</s></p><p><s>Interestingly, in the early period after KTx, there was a decrease in gene expression of CD247, GZMB, PRF1, and FOXP3, followed by a return to pre-KTx levels, in patients who were treated with basiliximab or without induction.</s><s>This finding can likely be explained by the decreased NK cell counts and the effect of maintenance therapy on gene expression.</s><s>The calcineurin-dependent mechanism of action involves the binding of CNIs to their respective immunophilins.</s><s>CNIs inhibit the transcription of proinflammatory and T cell-recruiting cytokines, such as interleukin (IL)-2 <ref type="bibr" target="#b25">[26]</ref>.</s><s>IL-2 regulates the gene expression of perforin and granzyme <ref type="bibr" target="#b26">[27]</ref>.</s><s>It directly promotes the transcription of FoxP3 <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s>Moreover, IL-2 has been shown to augment TCR-Œ∂ (CD247) expression in chronic inflammation <ref type="bibr" target="#b29">[30]</ref>.</s></p><p><s>While the expressions of CD247, GZMB, PRF1, and FOXP3 were downregulated, MAN1A1, TLR5 and TCAIM transcripts were upregulated early after KTx in all groups.</s><s>These transcripts might be expressed preferentially by other cell types than T cells which are more susceptible to induction and maintenance immunosuppression.</s><s>TCAIM, MAN1A1 and TLR5 are expressed not only by T cells, but also by macrophages/monocytes and dendritic cells <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref>.</s><s>The Indices of Tolerance Research Network ranked TLR5 as one of the top-10 gene markers for distinguishing between drug-free operationally tolerant and chronically rejecting kidney recipients.</s><s>Specifically, TLR5 was highly expressed in patients with chronic rejection, whereas it was downregulated in tolerant patients <ref type="bibr" target="#b4">[5]</ref>.</s><s>Similarly, increased expression of the other member of toll-like receptors TLR4 was observed in kidney transplant recipients with chronic rejection compared to operationally tolerant patients <ref type="bibr" target="#b35">[36]</ref>.</s><s>After haematopoietic stem cell transplantation, patients experiencing graft-versus-host disease had increased peripheral TLR5 expression; adoptive Treg therapy reduced this expression by preventing the disease <ref type="bibr" target="#b33">[34]</ref>.</s><s>Although the differences in TLR5 expression in our study were statistically significant, the clinical significance remains questionable.</s></p><p><s>TCAIM has been shown to be highly expressed during the induction and maintenance of operational tolerance to donor alloantigens in vivo, resulting in the acceptance of kidney and heart allografts in rats and mice <ref type="bibr" target="#b5">[6]</ref>.</s><s>TCAIM expression was downregulated in the peripheral blood and the graft before rejection.</s><s>This downregulation has been shown to occur in graft-infiltrating cells and after T-cell activation in vitro <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b36">37]</ref>.</s><s>The TCAIM protein is localized exclusively within mitochondria.</s><s>TCAIM-expressing murine T cells have been shown to be more susceptible to apoptosis <ref type="bibr" target="#b37">[38]</ref>.</s><s>An increased TCAIM mRNA level was described after administration of regulatory macrophages to patients before livingdonor KTx <ref type="bibr" target="#b38">[39]</ref>.</s><s>In a rat KTx model, intragraft expression of TCAIM was dramatically reduced in untreated rejecting recipients and in recipients who received an adoptive transfer of memory T cells <ref type="bibr" target="#b39">[40]</ref>.</s><s>Recently, it was shown that TCAIM inhibited spontaneous development of memory and effector T cells <ref type="bibr" target="#b40">[41]</ref>.</s><s>Higher FOXP3 and TCAIM expressions along with Treg numbers in basiliximab group may suggest a protective potential of basiliximab.</s><s>Here we showed that basiliximab induction was associated with a transient increase in absolute numbers of CD4 + FoxP3 + Tregs which was in line with findings of Bluestone et al. <ref type="bibr" target="#b41">[42]</ref>.</s><s>However the debate has not been finished yet and there are also other observations <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b43">44]</ref>.</s><s>The rATG induction resulted in long-lasting and profound depletion of absolute numbers of CD4 + FoxP3 + Tregs that corresponded to decreased level of FOXP3 gene expression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Induction immunosuppression with rATG was associated with long-lasting suppression of T and NK cell-associated genes, and with the upregulation of markers associated with rejection, MAN1A1 and TLR5, within the first month after KTx.</s><s>In contrast, basiliximab induction resulted in a fast increase in CD4 + FoxP3 + Tregs and expression of some markers associated with operational tolerance.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 Fig. 2</head><label>12</label><figDesc><div><p><s>Fig. 1 Effect of different inductive agents on the absolute numbers of T and NK cells in the peripheral blood of kidney transplant recipients during a 1-year follow-up period.</s><s>Absolute numbers of T cells (a), CD8 + T cells (b), NK cells (c), and CD4 + FOXP3 + Tregs (d) measured by flow cytometry in the peripheral blood from patients treated with rATG (squares on dashed line), basiliximab (triangles on dotted line), or without induction (circles on solid line).</s><s>Data are presented as estimated marginal means ¬± SEM</s></p></div></figDesc><graphic coords="5,127.28,96.27,340.76,235.28" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="6,127.28,96.27,340.76,364.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic characteristics at the time of transplantation</s></p></div></figDesc><table><row><cell>Variable</cell><cell>No-induction</cell><cell>rATG</cell><cell>Basiliximab</cell><cell>P value</cell></row><row><cell>Number</cell><cell>19</cell><cell>24</cell><cell>17</cell><cell></cell></row><row><cell>Gender (M/F)</cell><cell>9/10</cell><cell>16/8</cell><cell>9/8</cell><cell>ns  ‚Ä†</cell></row><row><cell>Recipient age (years)*</cell><cell>57 [27; 70]</cell><cell>54 [21; 78]</cell><cell>53 [25; 65]</cell><cell>ns  ‚Ä°</cell></row><row><cell>Donor age (years)*</cell><cell>52 [16; 68]</cell><cell>46 [18; 74]</cell><cell>61 [21; 75]</cell><cell>&lt;0.05  ‚Ä°a</cell></row><row><cell>HLA MM*</cell><cell>3 [2; 6]</cell><cell>3 [1; 5]</cell><cell>3 [2; 5]</cell><cell>ns  ‚Ä°</cell></row><row><cell>1 st /2 nd and 3 rd KTx (n)</cell><cell>19/0</cell><cell>11/13  ¬ß</cell><cell>16/1</cell><cell>&lt;0.0001  ‚Ä†</cell></row><row><cell>PRA (%)*</cell><cell>4 [0; 22]</cell><cell>68 [0; 96]</cell><cell>6 [2; 63]</cell><cell>&lt;0.0001  ‚Ä°b</cell></row><row><cell>CNI (TAC/CsA) (n)</cell><cell>21/4</cell><cell>28/0</cell><cell>18/0</cell><cell>ns  ‚Ä†</cell></row><row><cell>CIT (hours)*</cell><cell>16.2 [11.0; 20.7]</cell><cell>15.4 [7.7; 20.1]</cell><cell>17.2 [7.7; 21.0]</cell><cell>ns  ‚Ä°</cell></row><row><cell>Dialysis time (years)*</cell><cell>2.0 [0.2; 5.7]</cell><cell>1.9 [0.5; 6.4]</cell><cell>2.0 [0.6; 4.9]</cell><cell>ns  ‚Ä°</cell></row><row><cell>Cause of renal failure</cell><cell></cell><cell></cell><cell></cell><cell>ns  ‚Ä†</cell></row><row><cell>Primary GN</cell><cell>9</cell><cell>9</cell><cell>4</cell><cell></cell></row><row><cell>Hereditary diseases</cell><cell>2</cell><cell>5</cell><cell>4</cell><cell></cell></row><row><cell>Diabetic or ischemic nephropathy</cell><cell>6</cell><cell>2</cell><cell>7</cell><cell></cell></row><row><cell>TIN</cell><cell>2</cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>ANCA vasculitis or lupus nephritis</cell><cell>0</cell><cell>4</cell><cell>0</cell><cell></cell></row><row><cell>Other causes</cell><cell>0</cell><cell>3</cell><cell>1</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>the</cell></row><row><cell>no-induction or basiliximab group</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>¬ß 2 patients had a 3 rd transplantation</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ANCA Anti-neutrophil cytoplasmic antibodies, CIT cold ischemic time, CNI calcineurin inhibitor, CsA cyclosporine A, GN glomerulonephritis, HLA MM HLA mismatch, PRA historical panel-reactive antibodies, measured every 3 months before transplantation (the highest number in each patient was considered), TAC tacrolimus, TIN tubulointerstitial nephritis, TxR renal transplantation *Median [min; max]; ‚Ä† Chi square test P value; ‚Ä° Kruskal-Wallis test P value Dunn's Multiple Comparison Test: a Significant difference between the basiliximab group and the rATG group and a b significant difference between rATG andResultsPatient survival, graft function, and rejectionOne of the 60 patients died during the follow-up period (day 223 after KTx) due to acute myocardial infarction.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Graft function at 12 months post transplantation</s></p></div></figDesc><table><row><cell>Variable</cell><cell cols="2">No-induction rATG</cell><cell cols="2">Basiliximab P value</cell></row><row><cell>SCr (Œºmol/L)*</cell><cell>120</cell><cell>121</cell><cell>137</cell><cell>ns  ‚Ä°</cell></row><row><cell></cell><cell>[73; 260]</cell><cell>[51; 261]</cell><cell>[82; 246]</cell><cell></cell></row><row><cell cols="2">eGFR (mL/s/1.73 m 2 )* 0.80</cell><cell>0.89</cell><cell>0.65</cell><cell>ns  ‚Ä°</cell></row><row><cell></cell><cell>[0.28; 1.18]</cell><cell>[0.38; 1.81]</cell><cell>[0.34; 1.45]</cell><cell></cell></row><row><cell>Proteinuria (g/24)*</cell><cell>0.18</cell><cell>0.18</cell><cell>0.25</cell><cell>ns</cell></row><row><cell></cell><cell>[0.07; 2.58]</cell><cell>[0.07; 11.58]</cell><cell>[0.08; 1.11]</cell><cell></cell></row></table><note><p><s>‚Ä° eGFR estimated glomerular filtration rate, SCr serum creatinine *Median [min; max]; ‚Ä° Kruskal-Wallis test P value frequency peaked at day 21 (to 303 % of the pre-KTx value) and remained high (194 % of the pre-KTx value)</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>This study was supported by grants from the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR NT14102-3/2013, NS10517-3/2009, and NT11227-5/2010), the Grant Agency of the Czech Republic (P301/11/1568), the European Regional Development Fund (ED2.1.00/03.0076),</s><s>and the 7FP program of EU BioDrim and MABSOT.</s><s>The authors are indebted to Romana Polackova, Martina Ondrakova, Katarina Barcikova, Eva Faberova, and Adela Sajdlova for their technical assistance and coordination of sample collection, as well as to the patients and nurses for their cooperation and help.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Prevention of cardiovascular disease in adult recipients of kidney transplants</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Jardine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Gaston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Fellstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holdaas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="1419" to="1427" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine</title>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramaswamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Qian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="page" from="947" to="954" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Opelz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wiesel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Susal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1121" to="1127" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Paris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arango</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arbelaez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Garcia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1541" to="1547" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans</title>
		<author>
			<persName><forename type="first">P</forename><surname>Sagoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Perucha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tomiuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miqueu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1848" to="1861" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Identification of gene markers for the prediction of allograft rejection or permanent acceptance</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bushell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Steger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Risch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Siepert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1091" to="1102" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Contrasting CD25hiCD4 + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Braudeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dupont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Moizant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Robillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="398" to="407" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Iwase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kodera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuzuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iwasaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="191" to="198" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Mechanisms of rejection: current perspectives</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baniyash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="675" to="687" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Mechanisms of tolerance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bluestone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">241</biblScope>
			<biblScope unit="page" from="5" to="19" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Structure and function of Class I alpha 1,2-mannosidases involved in glycoprotein synthesis and endoplasmic reticulum quality control</title>
		<author>
			<persName><forename type="first">A</forename><surname>Herscovics</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochimie</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="757" to="762" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients</title>
		<author>
			<persName><forename type="first">Kidney</forename><surname>Disease</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S1" to="155" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Krystufkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sekerkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Striz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Brabcova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Girmanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Viklicky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2576" to="2582" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Immune reconstitution following rabbit antithymocyte globulin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gurkan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Luan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dhillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Allam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Montague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Bromberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2132" to="2141" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Vondran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Timrott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kollrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="514" to="523" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (&apos;CAN&apos;)</title>
		<author>
			<persName><forename type="first">K</forename><surname>Solez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Colvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Racusen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Halloran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Birk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="518" to="526" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="496" to="503" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Quantification of circulating regulatory T cells by flow cytometry in kidney transplant patients after basiliximab induction therapy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Abadja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Alamartine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Berthoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mariat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Genin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="366" to="368" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bouvy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cadogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kraaijeveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Baan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Weimar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Immunol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="186" to="190" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sageshima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ciancio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Gaynor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zarak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Immunol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="104" to="111" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/ azathioprine</title>
		<author>
			<persName><forename type="first">H</forename><surname>Vacher-Coponat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brunet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Moal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loundou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lyonnet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="558" to="566" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Natural killer cell receptor-repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hadaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Avila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Valloton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>De Rham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bandelier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferrari-Lacraz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="250" to="260" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Sewgobind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Van Der Laan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Hendrikx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Dam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Tilanus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1635" to="1644" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period</title>
		<author>
			<persName><forename type="first">T</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Opelz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wiesel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Feustel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Ott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="217" to="224" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pharmacology of calcineurin antagonists</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kapturczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Meier-Kriesche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="25S" to="32S" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Janas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Groves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kienzle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kelso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="8003" to="8010" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3 + regulatory T cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Burchill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vogtenhuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Blazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Farrar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="280" to="290" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Murawski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Litherland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Clare</forename><forename type="middle">-</forename><surname>Salzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Davoodi-Semiromi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1079</biblScope>
			<biblScope unit="page" from="198" to="204" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">T</forename><surname>Cheriyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Balaram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1435" to="1444" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">TCAIM decreases T cell priming capacity of dendritic cells by inhibiting TLR-induced Ca2+ influx and IL-2 production</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schlickeiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jurchott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Akyuez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Appelt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="3136" to="3146" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Toll-like receptor control of the adaptive immune responses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Iwasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Medzhitov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="987" to="995" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kerst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Handgretinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Muller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Hematol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1212" to="1218" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brunstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meisel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Appelt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="173" to="182" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5</title>
		<author>
			<persName><forename type="first">S</forename><surname>Uematsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishiyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="769" to="776" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Braudeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ashton-Chess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dugast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pallier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="130" to="136" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Differential expression and function of alpha-mannosidase I in stimulated naive and memory CD4+ T cells</title>
		<author>
			<persName><forename type="first">I</forename><surname>Gebuhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Keeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>H√∂flich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Appelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlieer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="428" to="437" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Keeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Friedrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gebuhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Philipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sabat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sterry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="4077" to="4087" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Riquelme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tomiuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miqueu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zuhayra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="2072" to="2078" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Siepert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahrlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Appelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stanko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>K√ºhl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2384" to="2394" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The Mitochondrial Protein TCAIM Regulates Activation of T Cells and Thereby Promotes Tolerance Induction of Allogeneic Transplants</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stanko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Woertge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Appelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>K√ºhl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2723" to="2735" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bluestone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Yabu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Laszik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Putnam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Belingheri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2086" to="2096" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">CD25 appears non essential for human peripheral T(reg) maintenance in vivo</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>De Goer De Herve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gonzales</forename><forename type="middle">E</forename><surname>Hendel-Chavez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>D√©cline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Mourier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Abbed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e11784</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bouvy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klepper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Betjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Weimar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1587" to="1597" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
